Reports

425 Results (Page 10 of 17)

Germany Markets Research Reports

Pharmaceuticals

Germany Radiotherapy Market Analysis

By 2030, it is anticipated that the German radiotherapy Market will reach a value of $11.1 Bn from $6.6 Bn in 2022, growing at a CAGR of 6.6% during 2022-30. The Radiotherapy Therapeutics Market in Germany is dominated by a few domestic players such as Brainlab, Eckert & Ziegler, and Ziehm Imaging. The radiotherapy market in Germany is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for German radiotherapy is increasing on account of the rise in cancer cases in the country.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Oct, 2023 | PRICE: $3999

Rare Diseases

Germany Multiple Myeloma Therapeutics Market Analysis

Germany's Multiple Myeloma Therapeutics Market was valued at $305 Mn in 2022 and is estimated to expand at a CAGR of 2.7% from 2022-30 and will reach $378 Mn in 2030. One of the main reasons propelling the growth of this Market is an increase in chronic disease, Increasing adoption of combination therapies. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Abbott, MorphoSys, Merck, Medigene, Affimed, Helios Hospital, Vivantes Hospital Group and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Sep, 2023 | PRICE: $3999

Pharmaceuticals

Germany Oral Care Market Analysis

Germany's oral care market was valued at $1.29 Bn in 2022 and is estimated to expand at a CAGR of 4.4% from 2022 to 2030 and will reach $1.82 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, Increasing prevalence of dental diseases. The market is segmented by type, drug, and distribution channel. Some key players in this market are Elmex, Meridol, Dr. Best, Dontodent, blend-a-dent Biorepair, Odol-med3, Listerine, and Kukident.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Aug, 2023 | PRICE: $3999

Healthcare Services

Germany Patient Support Programs (PSP) Market Analysis

Germany Patient Support Programs (PSP) market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of 8.1% for the year 2022-2030. The major factor responsible for the Germany Patient Support Programs (PSP) market is the increasing demand for patient-centric care for managing diseases in Germany. The market is segmented by functionality outlook, therapeutic outlook, application outlook, and end user. Some of the major PSP operators in the Germany Patient Support Programs (PSP) market are Ashfield Engage, CEBIS International, and Vitartis Medical Service.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Aug, 2023 | PRICE: $3999 $2999

Digital Health

Germany Telemedicine Market Analysis

This report presents a strategic analysis of the Germany Telemedicine Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany Telemedicine Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999 $2999

Pharmaceuticals

Germany Obesity Drugs Market Analysis

This report presents a strategic analysis of the Germany Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Germany Obesity Drugs Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Pharmaceuticals

Germany Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

Germany's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $668 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.3% from 2022-30 and will reach $1010 Mn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate and government initiative. The market is segmented by Drug class and by distribution channel. Some key players in this market are Kaia Health, Grifols, Riemser, Adamis Pharmaceuticals Corporation, Almirall, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva Germany Limited, and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Pharmaceuticals

Germany Anti Aging Therapeutics Market Analysis

Germany's anti-ageing therapeutics market is projected to grow from $22 Mn in 2022 to $66 Mn in 2030 with a CAGR of 14.73% for the year 2022-30. The major factors responsible for the expansion of the market are the increased demand for anti-ageing treatment options as a result of the rising elderly population. The German anti-ageing therapeutics market is segmented by product, treatment, target group, type of ageing, type of molecules, mechanism of action, ingredient, and by distribution channel. Some of the leading players in the market include CureVac, Rentschler Biopharma, and Advancells.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Acromegaly Therapeutics Market Analysis

Germany Acromegaly Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence and incidence of acromegaly and pituitary tumours are rising, as is global awareness of the disease. Technological advances in the development of new acromegaly medications are also key contributors to the market's growth. The high prevalence of hormonal problems, evolving lifestyles, and rising genetic disease incidence are all anticipated to fuel market expansion.Some of the key players in the global acromegaly therapeutics Market include Roche, Sanofi, GSK, Pfizer INC., Ipsen, Chiasma Inc, Validus pharmaceuticals LLC., Novartis AG, Amryt, Recordati, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals , and Others.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Adrenoleukodystrophy (ALD) Therapeutics Market Analysis

Germany Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Germany Adrenoleukodystrophy (ALD) drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Alport Syndrome Therapeutics Market Analysis

Germany during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Anal Fistula Therapeutics Market Analysis

Germany During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Angelman Syndrome Therapeutics Market Analysis

Germany During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Ankylosing Spondylitis Therapeutics Market Analysis

Germany Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Uveitis Therapeutics Market Analysis

Germany Uveitis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Uveitis is an inflammation of the uvea, which is the middle layer of the tissue that surrounds the eye and is made up of the iris, ciliary body, and choroid. The most typical extra-articular Spondyloarthritis symptom is uveitis (SpA) Increased healthcare financing, together with the development of drugs with improved efficacy and fewer side effects, has benefited technological advancements in the field, which together are serving as a potential driver of the uveitis therapeutic market. Several well-known companies involved in the development and marketing of uveitis medicines include Novartis AG, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, AbbVie Inc., and Allergan (now a division of AbbVie).

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Anthrax Therapeutics Market Analysis

Germany Anthrax therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Bacillus anthracis is the bacteria that causes anthrax (B. anthracis). The market for anthrax therapeutics is fueled by factors such the increased prevalence of bacterial infections, rising research funding, the development of innovative medicines for treating anthrax, and pipeline goods, which increase demand and stimulate market expansion. The current rise in healthcare spending in both developed and developing nations is anticipated to give manufacturers a competitive edge in the development of novel and ground-breaking products. Global industries in the Anthrax therapeutics market are Aristo Pharmaceuticals Private Limited, Indoco Remedies Ltd., Lupin, Deinove, Bayer AG, Pfizer Inc., Emergent, Soligenix, Zydus Group, Sanofi, Alembic Pharmaceuticals, Emergent, Sanofi, Porton Biopharma, Lupin, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and many more

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis

Germany ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Basal Cell Carcinoma Therapeutics Market Analysis

Germany Basal Cell Carcinoma Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most typical type of skin cancer and the most typical type of cancer overall is basal cell carcinoma (BCC). Rarely can basal cell carcinoma appear in mucous membranes; it typically appears on sun-damaged skin. The market for Basal Cell Carcinoma Therapeutics is being driven by an increase in the occurrence of skin cancers and better treatment options. The high cost of care and basal cell carcinoma's high propensity for underdiagnosis, however, are anticipated to impede the market's expansion. The high cost of care and basal cell carcinoma's high propensity for underdiagnosis, however, are anticipated to impede the market's expansion. Companies like MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others are active in the basal cell carcinoma market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Batten's Disease (CLN-2) Therapeutics Market Analysis

Germany Batten?s Disease (CLN-2) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neuronal Ceroid Lipofuscinosis (NCL), often known as Batten disease, is a rare and severe autosomal recessive neurodegenerative lysosomal storage condition brought on by cellular buildup of aberrant auto-fluorescent lipoproteins (lipofuscin). Seizures and a progressive loss of movement, verbal, visual, and cognitive abilities are features of this neurodegenerative condition that primarily affects the nerve system. Research advancements in nanotechnology could result in the creation of fresh therapies that would benefit persons who suffer from this ailment. Additionally, it is a paediatric brain condition that is extremely rare yet progresses quickly. As a result, Batten's Disease may be exacerbated by the predicted rising prevalence of disease. Therapeutics market (CLN-2). The market for Batten's Disease (CLN-2) Therapeutics is constrained by a lack of treatment and symptoms that are challenging to identify. Regenxbio, Polaryx Therapeutics and Abeona Therapeutics are some of the key players in the market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Charcot-Marie-Tooth Disease (CMT) Therapeutics Market Analysis

Germany Charcot-Marie-Tooth Disease (CMT) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The majority of hereditary peripheral neuropathies are Charcot-Marie-Tooth (CMT) illness, commonly referred to as hereditary motor and sensory neuropathy (HMSN). Genes that support or generate proteins important in the construction and operation of the myelin sheath or the peripheral nerve axon are mutated, leading to CMT. An increase in genetic illnesses will result in more innovations being made in this area, which will enhance market growth because there are many genes that cause these problems. The above-mentioned forecast period will witness the emergence of the market for Charcot Marie-Tooth disease due to multiple prospects that will be heightened by the rising focus on targeted therapies and the favorable government regulations. Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp., Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. are some of the major players in the Charcot Marie Tooth Disease Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis

Germany Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Chronic Lymphocytic Leukemia Therapeutics Market Analysis

Germany Chronic Lymphocytic Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A typical form of adult Leukemia known as chronic lymphocytic Leukemia (CLL) is characterized by an excessive production of aberrant white blood cells. In most cases, it happens when the bone marrow generates damaged cells, which interfere with the formation of antibodies and eventually render them ineffective against infections. The rise in chronic lymphocytic Leukemia cases is anticipated to fuel market expansion throughout the anticipated time frame. The market will rise as a result of the various treatment options available and the familial history of chronic lymphocytic leukemia. The high cost of treatment, however, is anticipated to limit market expansion. AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Exelixis, Inc., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., MorphoSys AG, Ono Pharmaceutical Co., Ltd., and Amgen, Inc. are a few of the leading companies profiled in the chronic lymphocytic leukemia therapeutics market report.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Chronic Myelogenous Leukemia Therapeutics Market Analysis

Germany Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Colorectal Cancer Therapeutics Market Analysis

Germany Colorectal Cancer Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Colon cancer, commonly known as colorectal cancer (CRC), is a condition that affects the large intestine. It is a type of cancer that develops in the colon or rectum. The surge in product introductions and colorectal cancer awareness are two factors driving the global market for drugs to treat the disease. The high incidence of colorectal cancer, which contributes to high mortality rates, and the rising global desire for more potent treatments are additional important driving forces. Genentech, Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.), Bayer AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Ipsen Biopharmaceuticals, Inc., and numerous other global companies participate in the colorectal cancer therapeutics

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Germany Cryptococcosis Therapeutics Market Analysis

Germany Cryptococcosis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The pathogenic yeasts in the genus Cryptococcus that cause cryptococcosis have a wide range of clinical manifestations and are contagious throughout the world. Currently, Cryptococcus neoformans and Cryptococcus gattii are the two species of the bacteria most frequently linked to human illness. The market for disorders caused by cryptococcosis is expanding as a result of the rising prevalence of the condition and the availability of cutting-edge treatments. Bristol-Myers Squibb, Abbott Laboratories, Pfizer, Glenmark Pharmaceuticals, Bausch Health, Johnson & Johnson, Novartis AG, Janssen Biotech, Sigmapharm Laboratories, Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and many others are leading companies in the global market for Cryptococcosis therapeutics.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

subscribe to our newsletter
up